If everything unfolds as hoped for (ODD, stellar PH1 top line results, adaptive PH2/3 Healey 48 week trial, some gratuitous funding via non profits and other sources, successful trial results which effectively confirms what is currently being seen in all PH1 patients), these market prices for PAAOA will seem like a gift by April 2026. Ofcourse, highly likely that the company will either have licensed or been taken over by then if those inflection points occur.
Ann: PAA completes Phase 1 and files for Orphan Drug Designation, page-328
-
- There are more pages in this discussion • 103 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
-0.015(7.50%) |
Mkt cap ! $90.96M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 18.5¢ | $115.7K | 598.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 593392 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 4355 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |